clinical trial · NCT06079879
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Merck Sharp & Dohme LLC·phase3·recruiting·n = 340
Essential ThrombocythemiaBomedemstatAnagrelideBusulfanInterferon alfa/pegylated interferon alfa 2a/pegylated interferon alfa 2bRuxolitinib
brief summary
This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea. The primary study hypothesis is that bomedemstat is superior to the best available therapy with respect to durable clinicohematologic response (DCHR).
started
Dec 31, 2023
primary completion
Jul 30, 2027
completion
Aug 18, 2028
last updated
Apr 23, 2026
official title
A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) Versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia Who Have an Inadequate Response to or Are Intolerant of Hydroxyurea
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol